Business & Finance
BioPharmX incurs higher net loss of USD4.4m for the fiscal Q2 2019
31 August 2018 -

Pharmaceutical company BioPharmX Corporation (NYSE American:BPMX) disclosed on Thursday its net loss of USD4.4m (USD0.02 per share) for the fiscal Q2 2019.

This is a decline in earnings when compared with a lower net loss of USD3.7m (USD0.05 per share) during the prior fiscal year's second quarter.

Revenues, net of USD24,000 were generated in fiscal Q2 2018, a growth over revenues, net USD17,000 in the prior fiscal year's second quarter.

Total operating expenses of USD4.3m were recorded in the prior fiscal year's second quarter.

Login
Username:

Password: